Gilead Sciences (GILD)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
$135.82-0.40%
Close 2026-07-08 · 1-day change
Reading GILD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GILD free→NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
Reading GILD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GILD free→Intact: The reason to own it still holds.
Gilead grows product sales excluding Veklury to about $29.4 billion in 2026. Total revenue is expected near $30.2 billion this year. The Arcellx acquisition boosts its cancer drug portfolio. Profit margins and earnings remain stable with steady growth.
If product sales growth slows below 6.8% or revenue falls under $30 billion, earnings could weaken. The Arcellx deal might not add value soon. Competition or regulation could hurt sales and profits.
The price is about 4% above our fair value near $130. Analysts expect about 6% revenue growth. Our fair value is below the Street median, reflecting caution on growth and margins.
Breaks if: acquisition not completed or fails to add value by 2028
Finalize the acquisition of Arcellx to enhance oncology and inflammation portfolios.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 3 of last 3 quarters. Gilead completed the acquisition of Arcellx for $7.8 billion in 2026-Q1, fulfilling its strategic goal to enhance its oncology and inflammation portfolios. This acquisition is expected to be accretive in 2028 and beyond, indicating progress.
“Gilead completed the acquisition of Arcellx for $7.8 billion.”
“Gilead announced the acquisition of Arcellx.”
“Gilead entered into an agreement to acquire Arcellx.”
Breaks if: product sales excluding Veklury fall below $29.4B in FY26
Focus on growing product sales excluding Veklury, with a target of $29.4 billion to $29.8 billion for 2026.
Stated in 4 of last 4 quarters. Product sales excluding Veklury increased 8% year-over-year to $6.8 billion in 2026-Q1, reflecting consistent growth. The company has raised its full-year revenue guidance, indicating delivering on this priority.
“Product sales excluding Veklury increased 8% year-over-year to $6.8 billion.”
“Product sales excluding Veklury increased 7% year-over-year.”
“Product sales excluding Veklury increased 6% year-over-year.”
“Product sales excluding Veklury increased 5% year-over-year.”
Breaks if: total revenue falls below $30.0B in FY26
Continue to drive growth in overall product sales, targeting $30.0 billion to $30.4 billion for 2026.
Stated in 4 of last 4 quarters. Total first quarter 2026 revenues increased 4% to $7.0 billion, showing consistent growth. The company has raised its full-year revenue guidance, indicating it is delivering on maintaining strong overall product sales.
“Total first quarter 2026 revenues increased 4% to $7.0 billion.”
“Total revenues increased 3% year-over-year.”
“Total revenues increased 5% year-over-year.”
“Total revenues increased 4% year-over-year.”